Predict your next investment

Corporation
HEALTHCARE | Pharmaceuticals / Drugs
optimerpharma.com

See what CB Insights has to offer

Founded Year

1998

Stage

Acq - P2P | Acquired

Total Raised

$55.32M

Valuation

$0000 

About Optimer Pharmaceuticals

Optimer Pharmaceuticals is a Healthcare/Pharmaceuticals / Drugs company based in San Diego, California. Optimer Pharmaceuticals' investors include Jay Goldman Master, President International Development, Visium Asset Management, Baker Brothers Advisors, Broadfin Capital, Mediphase Venture Partners, CIDC, Prudence Venture Investment Corporation, Perceptive Advisors, DWS Investments, J. Goldman & Co., UBS, Iroquois Capital, Balyasny Asset Management, Tang Capital Management, HBK Investments, Deerfield Management and Enable Capital Management.

Optimer Pharmaceuticals Headquarter Location

10110 Sorrento Valley Road Suite C

San Diego, California, 92121,

United States

858-909-0736

Latest Optimer Pharmaceuticals News

Cubist to acquire Optimer Pharmaceuticals and Trius Therapeutics

Jan 2, 2018

Cubist to acquire Optimer Pharmaceuticals and Trius Therapeutics Cubist Pharmaceuticals has entered into two separate agreements to acquire Optimer Pharmaceuticals and Trius Therapeutics, as part of the company's Building Blocks of Growth strategy to strengthen its presence in acute care and hospital environments. Under a merger agreement, Cubist will acquire all of the outstanding shares of Optimer common stock for $10.75 per share in cash, or nearly $535m on a fully diluted basis, with total transaction valued at up to $801m. Merger with Optimer brings Cubist the first USFDA-approved antibacterial drug, DIFICID, indicated to treat Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age or older. Morgan Stanley & Co. is acting as the exclusive financial advisor and Ropes & Gray as legal counsel to Cubist, while JP Morgan Securities and Centerview Partners are acting as financial advisors and Sullivan & Cromwell as legal counsel to Optimer. The definitive agreement between Cubist and Trius involves acquisition of all outstanding shares of Trius for $13.50 per share in cash or approximately $707m on a fully diluted basis, with total transaction valued at up to $818m. Acquisition of Trius brings to Cubist a late-stage antibiotic candidate, tedizolid phosphate (TR-701), as well as several pre-clinical antibiotic programs. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone in development for the potential treatment of certain Gram-positive infections, including methicillin-resistant Staphylococcus aureus (MRSA). Barclays is acting as the exclusive financial advisor and Ropes & Gray as legal counsel to Cubist, whereas Citi and Centerview Partners are acting as financial advisors and Cooley as legal counsel to Trius. Both the transactions are likely to complete later this year, subject to required regulatory approvals and other customary closing conditions. Share:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Optimer Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Optimer Pharmaceuticals is included in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

11,639 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

Optimer Pharmaceuticals Patents

Optimer Pharmaceuticals has filed 25 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/20/2012

12/1/2015

Prodrugs, Macrolide antibiotics, Antibiotics, Carbamates, Amines

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

12/20/2012

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

12/1/2015

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Prodrugs, Macrolide antibiotics, Antibiotics, Carbamates, Amines

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.